| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
874 Stock Overview
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People’s Republic of China and internationally.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$19.38 |
| 52 Week High | HK$24.00 |
| 52 Week Low | HK$18.02 |
| Beta | 0.61 |
| 1 Month Change | -8.37% |
| 3 Month Change | -5.69% |
| 1 Year Change | -7.05% |
| 3 Year Change | -40.82% |
| 5 Year Change | -4.77% |
| Change since IPO | 1,346.27% |
Recent News & Updates
Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ( HKG:874 ) will increase its dividend on the 14th of July...
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Does the April share price for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ( HKG:874 ) reflect what...
Shareholder Returns
| 874 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -1.5% | -1.9% | 1.5% |
| 1Y | -7.0% | -36.7% | -20.8% |
Return vs Industry: 874 exceeded the Hong Kong Pharmaceuticals industry which returned -36.7% over the past year.
Return vs Market: 874 exceeded the Hong Kong Market which returned -20.8% over the past year.
Price Volatility
| 874 volatility | |
|---|---|
| 874 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 12.8% |
| 10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 874 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 874's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 25,437 | Hong Li | https://www.gybys.com.cn |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People’s Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Fundamentals Summary
| 874 fundamental statistics | |
|---|---|
| Market Cap | HK$49.55b |
| Earnings (TTM) | HK$4.51b |
| Revenue (TTM) | HK$80.40b |
7.0x
P/E Ratio0.4x
P/S RatioIs 874 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 874 income statement (TTM) | |
|---|---|
| Revenue | CN¥69.51b |
| Cost of Revenue | CN¥55.98b |
| Gross Profit | CN¥13.52b |
| Other Expenses | CN¥9.62b |
| Earnings | CN¥3.90b |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 19, 2022
| Earnings per share (EPS) | 2.40 |
| Gross Margin | 19.45% |
| Net Profit Margin | 5.61% |
| Debt/Equity Ratio | 32.1% |
How did 874 perform over the long term?
See historical performance and comparison